CA2164113A1 - In situ gel for therapeutic use - Google Patents

In situ gel for therapeutic use

Info

Publication number
CA2164113A1
CA2164113A1 CA 2164113 CA2164113A CA2164113A1 CA 2164113 A1 CA2164113 A1 CA 2164113A1 CA 2164113 CA2164113 CA 2164113 CA 2164113 A CA2164113 A CA 2164113A CA 2164113 A1 CA2164113 A1 CA 2164113A1
Authority
CA
Canada
Prior art keywords
composition according
composition
solution
drug
mos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2164113
Other languages
English (en)
French (fr)
Inventor
Johan Carlfors
Katarina Edsman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2164113A1 publication Critical patent/CA2164113A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA 2164113 1993-06-02 1994-06-01 In situ gel for therapeutic use Abandoned CA2164113A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9301877-8 1993-06-02
SE9301877A SE9301877D0 (sv) 1993-06-02 1993-06-02 In situ gel for therapeutic use

Publications (1)

Publication Number Publication Date
CA2164113A1 true CA2164113A1 (en) 1994-12-08

Family

ID=20390132

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2164113 Abandoned CA2164113A1 (en) 1993-06-02 1994-06-01 In situ gel for therapeutic use

Country Status (6)

Country Link
EP (1) EP0706372A1 (de)
JP (1) JPH08510731A (de)
AU (1) AU6940594A (de)
CA (1) CA2164113A1 (de)
SE (1) SE9301877D0 (de)
WO (1) WO1994027578A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2287597A (en) * 1996-03-13 1997-10-01 Laboratoires Merck Sharp & Dohme - Chibret Snc Ophthalmological composition of the type which undergoes liquid-gel phase tr ansition
FR2746014B1 (fr) * 1996-03-13 1999-01-08 Composition ophtalmologique du type subissant une transition de phase liquide-gel
FR2754712B1 (fr) 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
EP0946197A1 (de) * 1996-11-29 1999-10-06 Monsanto Company Gleitfähiges formbeständiges (intaktes) gel zur oralen verabreichung biologosch aktiver stoffe
JP2004189731A (ja) * 2002-11-26 2004-07-08 Taisho Pharmaceut Co Ltd 点鼻剤
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
JP5304108B2 (ja) * 2007-08-30 2013-10-02 大正製薬株式会社 点眼剤
DE102010023949A1 (de) * 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ Lecithin-Mikroemulsionsgel-Formulierung
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
EP3233098B1 (de) 2014-12-15 2024-05-29 The Johns Hopkins University Cvs-transplantation zur behandlung von bakterieller vaginose
CA2974715C (en) 2015-01-27 2020-05-05 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN109260146A (zh) * 2018-10-12 2019-01-25 广州大光制药有限公司 地夸磷索钠眼用即用型凝胶滴眼液及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
FR2657018A1 (fr) * 1990-01-12 1991-07-19 Merck Sharp & Dohme Composition ophtalmique fluide a base de microparticules lipidiques contenant au moins un principe actif et son procede de preparation.
CA2040460C (en) * 1990-05-01 1997-06-10 Tacey X. Viegas Drug delivery with thermoreversible gels
DE69212850T2 (de) * 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen

Also Published As

Publication number Publication date
WO1994027578A1 (en) 1994-12-08
SE9301877D0 (sv) 1993-06-02
AU6940594A (en) 1994-12-20
EP0706372A1 (de) 1996-04-17
JPH08510731A (ja) 1996-11-12

Similar Documents

Publication Publication Date Title
KR940000229B1 (ko) 생리학적 액체와 접촉하여 겔화되는 약제학적 조성물의 제조방법
US20240197657A1 (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
EP0844868B1 (de) O-Carboxymethylchitosan enthaltende Mittel und ihre Verwendung in Ophthalmika
US9216167B2 (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
CN101312711B (zh) 不含右泛醇、钙离子和磷酸盐的药物组合物以及钙螯合剂和眼科相容粘度调节剂的应用
JP2015038099A (ja) 防腐剤を含まない非粘性プロスタグランジン系点眼液用のポリマー送達システム
US20100234318A1 (en) Ophthalmic composition containing alginic acid or salt thereof
MX2011013107A (es) Composiciones farmaceuticas acuosas que contienen complejos de borato - poliol.
US7998942B2 (en) Eye drop preparation comprising xanthan gum and terpenoid
CA2164113A1 (en) In situ gel for therapeutic use
FR2660193A1 (fr) Produit opthalmique comportant des nanocapsules, son procede de preparation et utilisation des nanocapsules.
WO2001001959A1 (en) Ophthalmic compositions in form of aqueous gels
US5200180A (en) Pharmaceutical composition for the treatment of the human eye
AU2004305539B2 (en) Ophthalmic compositions containing a polysaccharide/borate gelling system
JP5041761B2 (ja) 眼粘膜適用製剤
CA2306371C (en) Use of flunarizine for the topical treatment of glaucoma
EP1749541B1 (de) Augentropfen
JPS63502270A (ja) 散瞳作用を有する眼科用医薬組成物
JP2003267892A (ja) 熱ゲル化人工涙液
US8679511B2 (en) In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead